Citeline Podcasts

Audio roundup of selected biopharma industry content from Scrip over the business week ended 14 February 2025. In this episode: delayed take-off for M&A?; Bain to acquire Mitsubishi Tanabe; clinical trials to look out for; how to work with Trump; and mid-cap biopharma winners and losers. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-th...

Pink Sheet Executive Editor Derrick Gingery, Editor-in-Chief Nielsen Hobbs, and special guest Michael McCaughan of Prevision Policy look at new Health and Human Services Secretary Robert F. Kennedy Jr.’s first assignment, a presidential commission on reducing chronic disease (:29), as well as former US Food and Drug Administration Commissioner Scott Gottlieb’s suggestion that industry extend the e...

Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends, and innovations from the JP Morgan Healthcare Conference. Discover what these developments mean for you and the future of the industry in 2025 and beyond.

트럼프 미 대통령의 재당선과 지정학적 불안요소가 제약바이오 시장과 기업에 어떤 영향을 미칠까? Scrip의 전문가 설문조사 기사를 요약한 내용입니다. https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2025-hold-for-biopharma-part-3-impacts-of-political-change-in-us-and-beyond-CKTDR3BC2JBU5O6MUHDAKXGXHU/ Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

Creativity can sometimes be about discovering what in retrospect seems obvious, like shoes that are shaped to fit our feet, marketing expert Beverley Law tells HBW Insight in the first episode of this season’s Over the Counter podcast. But this often requires stepping out of established approaches and patterns of thinking, she points out, which tend to characterise innovation in the consumer healt...

Audio roundup of selected biopharma industry content from Scrip over the business week ended 7 February 2025. In this episode: Novo outlines CagriSema strategy; Pfizer is back in the deal game; Vertex’s pain drug faces opportunities and headwinds; uncertain times for Korean pharma; and a view on women’s health at JPM. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-...

Introduction: Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the many commitments Robert F. Kennedy Jr. gave Sen. Bill Cassidy, R-LA, to secure his vote to move his Health and Human Services Secretary nomination to the Senate floor (:25). They also consider the slow restoration of some US Food and Dr...

Audio roundup of selected biopharma industry content from Scrip over the business week ended 31 January 2025. In this episode: biopharma VC fundraising recovers; Daiichi Sankyo’s big year ahead; Akero’s promising MASH results; ADCs attract new investments in China; and Scrip Asks on AI and data science. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-f...

Harness Therapeutics' CEO talked to In Vivo about the company's scientific strategy, and its plans for expansion and partnering in the neurodegeneration space.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter, and Editor-in-Chief Nielsen Hobbs discuss the effect of Acting US Food and Drug Administration Commissioner Sara Brenner’s use of MAHA in her introductory memo (:35), the issues that emerged during MAHA founder and Health and Human Services Secretary nominee Robert F. Kennedy Jr.’s Senate confi...

Summer Colling and Emma Wille speak with epidemiologists Ridwaan Ibrahim and Lucia Rodriguez-Garcia about the recent ISPOR conference. Ridwaan and Lucia discuss where they see new technologies like AI fitting into the epidemiology space as well as the advantages and disadvantages of using AI to analyze large volumes of real world data.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 24 January 2025. In this episode: semaglutide in 2027 Medicare price negotiations; J&J expects revenue growth despite challenges; Roche’s China Accelerator makes progress; Scrip Asks about the impact of political change; and Datroway’s US approval in breast cancer. https://insights.citeline.com/scrip/podca...

Pink Sheet reporter and editors try to answer some emerging questions about the US Food and Drug Administration now that President Donald Trump has taken office. They discuss the FDA’s acting leadership (:43), an ongoing communications freeze (7:45), along with the hiring freeze and travel ban (20:49). They also discuss the impact of several executive orders on the US Centers for Medicare and Medi...

In Vivo speaks with Ashley Zender, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals. The company's $494m partnership with Eli Lilly is a testament to the value of their approach.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 17 January 2025. In this episode: a look at JPM; J&J’s Intra-Cellular buy; how JPM Day 1 deals fit into BD strategy; Scrip asks about the global state of biopharma; and what will fuel M&A activity in India this year. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scr...

Pink Sheet editors consider ex-FDA officials’ advice for the Trump Administration on implementing FDA reforms (:24), comments CDER Director Patrizia Cavazzoni made before her departure from the agency about wanting to release review documents for applications that received complete response letters (12:35), and diverging trends between CDER and CBER novel application approvals (21:53). More On The...

Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions. In Vivo questions the current progress of their lead asset BEXMAB and its potential moving forward.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 10 January 2025. In this episode: key themes for JPM; 2024 launches a breakout for liver disease; obesity drug readouts this year; IgA nephropathy snapshot; and only half of 2024 launches were from big pharma. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-fiv...

Pink Sheet editors discuss Center for Drug Evaluation and Research Director Patrizia Cavazzoni’s surprising retirement announcement (:32), the importance of the large bolus of guidance documents that the FDA released 6 January (12:42), and the FDA’s decision to continue reviewing and granting rare pediatric disease designations even though the program lapsed (18:48). More On These Topics From The...

트럼프 대통령의 취임 직전 열리는 2025년 JP모건 헬스케어 컨퍼런스에서 라이센스딜 및 M&A 뿐 아니라 미국 정치와 정책도 주목 받을 것이라는 Scrip 기사의 요약입니다. https://insights.citeline.com/scrip/conferences/jp-morgan/jpm-2025-deals-politics-and-parties-to-welcome-a-new-year-for-pharma-5XBXOFPQMNB3ZBWVSWIIY5Y7IM/ Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.

In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.

In this week’s Digital Health Roundup, Medtech Insight’s Marion Webb brings highlights from Deloitte’s 2025 Life Sciences Outlook Report with medtech leaders’ forecasting significant investments in AI/GenAI. Brian Bossetta talks about the US FDA’s newly formed Digital Health Advisory Committee. Elizabeth Orr highlights the pros and cons of penetration testing for cybersecurity and talks about the...

Emma and Summer meet with Datamonitor Healthcare analyst Ken Hoang, to discuss the non-alcoholic steatohepatitis (NASH) treatment market

Scrip이 선정한 2024년의 Top 5 글로벌 제약바이오 뉴스입니다. https://insights.citeline.com/scrip/business/deals/the-top-five-pharma-stories-of-2024-GSROXP3WAZBWXGV4YP6VJML3YY/ Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini